![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Preview
The Food and Drug Administration has approved three antiretroviral agents for use in HIV-infected adults. Zidovudine is the most widely prescribed and is considered first-line therapy, but the best time to start the drug is uncertain. The authors emphasize the importance of flexibility in using these agents and discuss current recommendations for initiating and changing the therapeutic regimen.
Additional information
Notes on contributors
Danny J. Lancaster
Dr Danny J. Lancaster (left) is codirector of the internal medicine residency program at Methodist Hospitals of Memphis. He is also clinical associate professor of medicine, University of Tennessee, Memphis, College of Medicine. His interests Include HIV Infection and medical education.
Dr Laura L. Lancaster (right) is assistant professor of medicine, division of general internal medicine, University of Tennessee, Memphis, College of Medicine. Her interests include HIV Infection, fungal Infections, and geriatric medicine.
Laura L. Lancaster
Dr Danny J. Lancaster (left) is codirector of the internal medicine residency program at Methodist Hospitals of Memphis. He is also clinical associate professor of medicine, University of Tennessee, Memphis, College of Medicine. His interests Include HIV Infection and medical education.
Dr Laura L. Lancaster (right) is assistant professor of medicine, division of general internal medicine, University of Tennessee, Memphis, College of Medicine. Her interests include HIV Infection, fungal Infections, and geriatric medicine.